Anavex Life Sciences (NASDAQ:AVXL) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Anavex Life Sciences (NASDAQ:AVXL) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03, Zacks reports.

Anavex Life Sciences Stock Performance

Shares of AVXL opened at $8.63 on Monday. Anavex Life Sciences has a fifty-two week low of $3.25 and a fifty-two week high of $10.45. The firm has a 50-day simple moving average of $7.69 and a 200-day simple moving average of $6.19. The company has a market capitalization of $731.79 million, a price-to-earnings ratio of -17.26 and a beta of 0.73.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on AVXL. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Anavex Life Sciences in a report on Wednesday, November 27th. D. Boral Capital reaffirmed a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Monday, November 25th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.